Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
S. M. Keefe, J. Hoffman-Censits, R. B. Cohen, R. Mamtani, D. Heitjan, S. Eliasof, A. Nixon, B. Turnbull, E. G. Garmey, O. Gunnarsson, M. Waliki, J. Ciconte, L. Jayaraman, A. Senderowicz, A. B. Tellez, M. Hennessy, A. Piscitelli, D. Vaughn, A. Smith, Naomi B. Haas
Dive into the research topics of 'Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial'. Together they form a unique fingerprint.